{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:32:55Z","timestamp":1782977575086,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ymgme.2017.08.005","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T05:48:16Z","timestamp":1503553696000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Reductions in glucosylsphingosine (lyso-Gb1) in treatment-na\u00efve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials"],"prefix":"10.1016","volume":"122","author":[{"given":"Deborah","family":"Elstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Mellgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.08.005_bb0005","series-title":"Williams Hematology","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2016"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0010","first-page":"157","article-title":"Clinical manifestations and management of Gaucher disease","volume":"12","author":"Linari","year":"2015","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0015","series-title":"Advances in Gaucher Disease: Basic and Clinical Perspectives","first-page":"214","article-title":"Biomarkers","author":"Lorne","year":"2013"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0020","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcmd.2010.10.014","article-title":"Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease","volume":"46","author":"Stirnemann","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/1678-4685-GMB-2015-0125","article-title":"The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher disease","volume":"39","author":"Koppe","year":"2016","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cccn.2004.02.018","article-title":"Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy","volume":"344","author":"Cabrera-Salazar","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.24399","article-title":"Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase","volume":"91","author":"Pastores","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0055","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0060","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF02436762","article-title":"Elevated plasma chitotriosidase activity in various lysosomal storage disorders","volume":"18","author":"Guo","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0065","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10545-006-0363-3","article-title":"Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A\/B and C","volume":"29","author":"Ries","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cca.2009.09.034","article-title":"Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis","volume":"411","author":"Boot","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bcmd.1999.0221","article-title":"Plasma chitotriosidase activity in patients with beta-thalassemia","volume":"25","author":"Barone","year":"1999","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1742-2094-8-144","article-title":"Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy","volume":"8","author":"Orchard","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0085","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"van Dussen","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0090","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.rmed.2014.02.002","article-title":"Serial chitotriosidase measurements in sarcoidosis\u2014two to five year follow-up study","volume":"108","author":"Harlander","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0095","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","article-title":"The human chitotriosidase gene. Nature of inherited enzyme deficiency","volume":"273","author":"Boot","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1189\/jlb.1204712","article-title":"Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes","volume":"78","author":"Schutyser","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1471-4159.1982.tb07950.x","article-title":"Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease","volume":"39","author":"Nilsson","year":"1982","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0115","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0120","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcmd.2015.01.006","article-title":"Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard","volume":"54","author":"Mirzaian","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0145","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","article-title":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase","volume":"117","author":"Smith","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","volume":"90","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170268","article-title":"Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes","volume":"12","author":"Kallemeijn","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.08.005_bb0170","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3072586","article-title":"Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance","volume":"2016","author":"Song","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","article-title":"Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","volume":"59","author":"Pastores","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2017.08.005_bb0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1194\/jlr.M043802","article-title":"Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis","volume":"55","author":"Gaspar","year":"2014","journal-title":"J. Lipid Res."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921730433X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921730433X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T06:25:58Z","timestamp":1535437558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921730433X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":36,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S109671921730433X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reductions in glucosylsphingosine (lyso-Gb1) in treatment-na\u00efve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}